Tevogen Bio Holdings Stock Performance
| TVGN Stock | 1.14 0.03 2.56% |
On a scale of 0 to 100, Tevogen Bio holds a performance score of 3. The entity has a beta of 0.71, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tevogen Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Tevogen Bio is expected to be smaller as well. Please check Tevogen Bio's semi variance, as well as the relationship between the daily balance of power and price action indicator , to make a quick decision on whether Tevogen Bio's existing price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Tevogen Bio Holdings are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Tevogen Bio displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Whats Going On With Tevogen Bio Stock Today | 01/27/2025 |
2 | Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS Echoes Commitment to Innovation and Affordability for Americans | 02/13/2025 |
3 | Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nations Health and Prosperity | 02/14/2025 |
4 | Tevogen Bios First Trading Year Efficiency 600 percent Higher Market Cap Per Team Member, 79 percent ... | 02/21/2025 |
5 | Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating ... | 02/28/2025 |
6 | Which Biotechnology Firm Leads in Innovation and Financial Strength | 03/03/2025 |
7 | Disposition of 110659 shares by Flomenberg Neal of Tevogen Bio at 1.21 subject to Rule 16b-3 | 03/05/2025 |
8 | Disposition of 88519 shares by Flomenberg Neal of Tevogen Bio at 1.1 subject to Rule 16b-3 | 03/06/2025 |
9 | Tevogen Bios CIO Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauers AI Discussion Panel | 03/07/2025 |
10 | Disposition of 70252 shares by Flomenberg Neal of Tevogen Bio at 1.05 subject to Rule 16b-3 | 03/11/2025 |
11 | Disposition of 232968 shares by Flomenberg Neal of Tevogen Bio at 1.09 subject to Rule 16b-3 | 03/12/2025 |
| Begin Period Cash Flow | 129.2 K |
Tevogen |
Tevogen Bio Relative Risk vs. Return Landscape
If you would invest 107.00 in Tevogen Bio Holdings on December 24, 2024 and sell it today you would earn a total of 7.00 from holding Tevogen Bio Holdings or generate 6.54% return on investment over 90 days. Tevogen Bio Holdings is currently generating 0.3344% in daily expected returns and assumes 6.9472% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than Tevogen, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tevogen Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tevogen Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tevogen Bio Holdings, and traders can use it to determine the average amount a Tevogen Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0481
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TVGN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.95 actual daily | 62 62% of assets are less volatile |
Expected Return
| 0.33 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Tevogen Bio is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tevogen Bio by adding it to a well-diversified portfolio.
Tevogen Bio Fundamentals Growth
Tevogen Stock prices reflect investors' perceptions of the future prospects and financial health of Tevogen Bio, and Tevogen Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tevogen Stock performance.
| Return On Asset | -5.42 | ||||
| Current Valuation | 206.99 M | ||||
| Shares Outstanding | 175.05 M | ||||
| EBITDA | 188.71 K | ||||
| Net Income | (67.33 K) | ||||
| Total Debt | 1.63 M | ||||
| Book Value Per Share | (0.08) X | ||||
| Cash Flow From Operations | (1.38 M) | ||||
| Earnings Per Share | 0.35 X | ||||
| Market Capitalization | 199.56 M | ||||
| Total Asset | 17.04 M | ||||
| Retained Earnings | (17.38 M) | ||||
| Working Capital | (2.65 M) | ||||
About Tevogen Bio Performance
By examining Tevogen Bio's fundamental ratios, stakeholders can obtain critical insights into Tevogen Bio's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Tevogen Bio is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Equity | 0.10 | 0.11 |
Things to note about Tevogen Bio Holdings performance evaluation
Checking the ongoing alerts about Tevogen Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tevogen Bio Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tevogen Bio Holdings had very high historical volatility over the last 90 days | |
| Tevogen Bio Holdings may become a speculative penny stock | |
| Net Loss for the year was (67.33 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tevogen Bio generates negative cash flow from operations | |
| About 91.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Disposition of 232968 shares by Flomenberg Neal of Tevogen Bio at 1.09 subject to Rule 16b-3 |
- Analyzing Tevogen Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tevogen Bio's stock is overvalued or undervalued compared to its peers.
- Examining Tevogen Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tevogen Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tevogen Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tevogen Bio's stock. These opinions can provide insight into Tevogen Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tevogen Bio Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tevogen Bio. If investors know Tevogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tevogen Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Tevogen Bio Holdings is measured differently than its book value, which is the value of Tevogen that is recorded on the company's balance sheet. Investors also form their own opinion of Tevogen Bio's value that differs from its market value or its book value, called intrinsic value, which is Tevogen Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tevogen Bio's market value can be influenced by many factors that don't directly affect Tevogen Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tevogen Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tevogen Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tevogen Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.